Verdence Capital Advisors LLC Boosts Holdings in Pfizer Inc. $PFE

Verdence Capital Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 23.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 186,650 shares of the biopharmaceutical company’s stock after buying an additional 35,502 shares during the period. Verdence Capital Advisors LLC’s holdings in Pfizer were worth $4,623,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Curio Wealth LLC increased its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter worth approximately $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer during the second quarter valued at approximately $30,000. True Wealth Design LLC raised its holdings in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PFE shares. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. HSBC reiterated a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. UBS Group assumed coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Stock Down 0.8%

PFE opened at $25.68 on Tuesday. The stock has a market cap of $146.01 billion, a price-to-earnings ratio of 14.93 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm’s fifty day moving average is $25.38 and its 200 day moving average is $24.99. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.